1. Home
  2. HNI vs MLYS Comparison

HNI vs MLYS Comparison

Compare HNI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HNI Corporation

HNI

HNI Corporation

N/A

Current Price

$36.59

Market Cap

2.8B

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$22.91

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HNI
MLYS
Founded
1944
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
HNI
MLYS
Price
$36.59
$22.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$70.00
$48.67
AVG Volume (30 Days)
867.3K
1.1M
Earning Date
05-06-2026
03-12-2026
Dividend Yield
4.00%
N/A
EPS Growth
N/A
37.43
EPS
1.11
N/A
Revenue
$2,839,000,000.00
N/A
Revenue This Year
$117.47
N/A
Revenue Next Year
$3.55
N/A
P/E Ratio
$30.52
N/A
Revenue Growth
12.37
N/A
52 Week Low
$33.72
$10.44
52 Week High
$53.29
$47.65

Technical Indicators

Market Signals
Indicator
HNI
MLYS
Relative Strength Index (RSI) 29.60 29.08
Support Level N/A $13.42
Resistance Level $47.68 $31.09
Average True Range (ATR) 1.46 1.72
MACD -0.42 -0.27
Stochastic Oscillator 30.32 5.24

Price Performance

Historical Comparison
HNI
MLYS

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: